MS Speaks

Multiple Sclerosis => TREATMENTS => Topic started by: agate on October 28, 2017, 12:07:33 pm

Title: (ECTRIMS) Strike three for laquinimod in relapsing MS
Post by: agate on October 28, 2017, 12:07:33 pm

A MedPage Today article (October 28) discusses laquinimod findings presented at the ECTRIMS conference, held in Paris, October 25-28, 2017.

The last paragraph indicates that laquinimod is still a possibility for primary progressive MS:

Quote

Teva had earlier announced that CONCERTO failed to meet its primary endpoint, and therefore the company would not seek approval for the drug in relapsing MS. But it still has ongoing trials and development interest in laquinimod for primary progressive MS and for Huntington's disease.

"Strike three for laquinimod in relapsing MS" (https://www.medpagetoday.com/MeetingCoverage/ECTRIMS/68839?xid=nl_mpt_DHE_2017-10-28&eun=g345846d0r&pos=1)